Pregnancy outcome after treatment with radioiodine for differentiated thyroid carcinoma

Scientific paper - Original scientific paper

• Author: Antonija Balenović
• Author: Marko Vlašić
• Author: Zdenko Sonicki
• Author: Davor Bodor
• Author: Zvonko Kusić
• Author's institution: University of Zagreb; School of Medicine
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences

Abstract (english)

The aim of the study was to investigate the influence of radioiodine (RAI) therapy on pregnancies and the health status of children born to mothers who had received therapeutic doses of I-131 for differentiated thyroid carcinoma (DTC). Gestational histories of 76 women treated for DTC from 1971-2005 were retrospectively analyzed. The outcome of 49 pregnancies after RAI was: 35 children (72%), 5 (10%) miscarriages and 9 (18%) induced abortions. RAI did not adversely affect the rate of successful delivery and live birth demographics. Congenital malformation and first year mortality were not observed. The children's ages range from 1 month to 29 years (chi+/-SD=8.0+/-8.4). A higher therapeutic dose (>100 mCi) did not significantly alter the pregnancy outcome. There is no reason to discourage females treated with 1-131 from becoming pregnant. Patients should avoid pregnancy after RAI administration for 1 year.

Abstract (croatian)

Cilj studije bio je utvrditi utjecaj radioaktivnog joda (RAI) na trudnoće, kao i na zdravlje djece bolesnica koje su primale terapijske doze I-131 radi diferenciranog karcinoma štitnjače (DTC). Trudnoće u 76 bolesnica liječenih radi DTC-a u periodu od 1971.–2005. g. su retrospektivno analizirane. Ishod 49 trudnoća koje su uslijedile nakon terapije RAI bio je: 35 djece (72%), 5 spontanih pobačaja (10%) i 9 arteficijalnih pobačaja (18%). Terapija radioaktivnim jodom nije negativno utjecala na stopu uspješnih poroda, niti na demografske osobine novorođenčadi. Kongenitalne malformacije i mortalitet u prvoj godini života nisu registrirani. Srednja dob djece bila je 8 godina (raspon 1 mjesec do 29 godina, SD=8.4). U bolesnica koje su primile veće terapijske doze radioaktivnog joda (>100 mCi) nije registriran lošiji ishod. Bolesnicama liječenim radioaktivnim jodom radi diferenciranog karcinoma štitnjače nije potrebno preporučivati izbjegavanje trudnoće. Preporuča se izbjegavati trudnoću u godini neposredno nakon primanja terapije I-131.

• Keywords (english): Adenocarcinoma, Follicular - radiotherapy - surgery; Carcinoma, Papillary - radiotherapy - surgery; Iodine Radioisotopes - therapeutic use; Pregnancy Outcome; Thyroid Neoplasms - radiotherapy; Adolescent; Adult; Combined Modality Therapy; Female; Humans; Infant, Newborn; Male; Pregnancy; Thyroidectomy
• Language: english
• Publication type: Scientific paper - Original scientific paper
• Publication status: Published
• Peer review: Peer review
• Publication version: Published version
• Journal title: Collegium Antropologicum
• Numbering: vol. 30, no. 4, pp. 743-748
• p-ISSN: 0350-6134
• URN:NBN: urn:nbn:hr:105:642920
• Publication: 2006-12
• Document URL: https://hrcak.srce.hr/27632
• Type of resource: Text
• Access conditions: Open access
• Created on: 2024-03-28 11:03:20